{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:34:50Z","timestamp":1780396490039,"version":"3.54.1"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,7,26]],"date-time":"2015-07-26T00:00:00Z","timestamp":1437868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001275","name":"The Oak foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Safety data regarding the use of etoricoxib and other nonsteroidal antiinflammatory drugs (NSAIDs) in ankylosing spondylitis (AS) and other spondyloarthritis (SpA) patients are rather limited. Our objective was to estimate and compare rates of gastrointestinal, renovascular, and cardiovascular adverse events in patients exposed to etoricoxib, celecoxib, or nonselective NSAIDs or totally unexposed to NSAIDs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a national register\u2010based cohort study on patients with AS or SpA (n\u2009=\u200921,872) identified in the Swedish national patient register from 1987\u20132009. Treatment exposure was assessed time dependently based on the prescription drug register from 2006\u20132009, adjusting for sociodemographics and comorbidities derived from national population\u2010based registers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Exposure to etoricoxib, celecoxib, and nonselective NSAIDs was 7.6%, 3.9%, and 71.2%, respectively. No major risk differences for serious cardiovascular, gastrointestinal, or renal adverse events were seen among the 3 exposure groups. Patients unexposed to NSAIDs had more baseline comorbidities and an increased relative risk for congestive heart failure events during the study period (2.0, 95% confidence interval [95% CI] 1.3\u20133.2). The relative risk for atherosclerotic events was nonsignificant when compared to the nonselective NSAID group (1.0, 95% CI 0.7\u20131.5), while the relative risk for gastrointestinal events was lower for unexposed patients (0.5, 95% CI 0.4\u20130.7).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Overall, serious adverse events related to nonselective NSAIDs, etoricoxib, and celecoxib were similar and in the range of what would be expected in a group of SpA patients. Patients unexposed to NSAIDs had considerably more baseline comorbidities and increased risk for congestive heart failure, reflecting a selection of patients being prescribed NSAIDs in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.22555","type":"journal-article","created":{"date-parts":[[2015,1,26]],"date-time":"2015-01-26T14:32:31Z","timestamp":1422282751000},"page":"1137-1149","source":"Crossref","is-referenced-by-count":39,"title":["Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population\u2010Based Cohort Study"],"prefix":"10.1002","volume":"67","author":[{"given":"L. E.","family":"Kristensen","sequence":"first","affiliation":[{"name":"Copenhagen University Hospital, Frederiksberg, Denmark and Sk\u00e5ne University Hospital, Lund University Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. K.","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Malm\u00f6 University Hospital of Sk\u00e5ne Malm\u00f6 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Askling","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital Frederiksberg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. T. H.","family":"Jacobsson","sequence":"additional","affiliation":[{"name":"University of Gothenburg Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,26]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"S33","article-title":"Proton pump inhibitor co\u2010therapy with nonsteroidal anti\u2010inflammatory drugs: nice or necessary?","volume":"4","author":"Laine L.","year":"2004","journal-title":"Rev Gastroenterol Disord"},{"key":"e_1_2_7_3_1","first-page":"408","article-title":"Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial","volume":"34","author":"Baraf HS","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60234-7"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep005"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16894-3"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07598.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01407.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050493"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X43686"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050405"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90007-0"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.082388"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2012.08.005"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.045872"},{"key":"e_1_2_7_17_1","first-page":"S17","article-title":"The prevalence of ankylosing spondylitis in Sweden: a Nationwide Register Study [abstract]","volume":"66","author":"Exarchou S","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-eular.2817"},{"key":"e_1_2_7_19_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index 2015. URL:http:\/\/www.whocc.no\/atc_ddd_index."},{"key":"e_1_2_7_20_1","volume-title":"R: a language and environment for statistical computing","author":"Development Core Team","year":"2012"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.200810425"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1201\/9781420010404"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.141598"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151563"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2008.01931.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20408"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60900-9"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133371"},{"key":"e_1_2_7_29_1","unstructured":"The Center for Epidemiology. The Swedish National Board of Health and Welfare. URL:http:\/\/www.sos.se\/epc."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.22555","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.22555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:25:20Z","timestamp":1759418720000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.22555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,26]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1002\/acr.22555"],"URL":"https:\/\/doi.org\/10.1002\/acr.22555","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,26]]}}}